Becton Dickinson raises full-year adjusted earnings outlook after strong quarterly performance across most business segments.
Becton Dickinson reported fiscal second-quarter revenue of $4.7 billion, up 2.6% on an FX-neutral basis, exceeding internal expectations. Adjusted diluted earnings per share reached $2.90, with an operating margin of 24.2%.
Over 90% of the company’s portfolio delivered mid-single-digit growth, though pressures from Alaris, vaccines, and China impacted reported results. Double-digit growth was seen in biologic drug delivery, advanced patient monitoring, and other key platforms.
Management raised its full-year adjusted earnings outlook, citing broad-based resilience and focus on innovation and execution. Medical Essentials grew 1.7%, driven by U.S. strength in MDS and specimen management.